Grade	B:C0008902
Group	I:C0008902
Underestimation	O
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	B:C0243095
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	O
in	O
Prostate	B:C0194804
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	O
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	B:C0683956
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	O
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	B:C1518681
in	O
Candidates	O
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	O
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	B:C1257890
for	O
Active	O
Surveillance	I:C1827061
.	O

Grade	O
Group	I:C0008902
Underestimation	O
in	O
Prostate	O
Biopsy	I:C0194804
:	O
Predictive	O
Factors	I:C0683956
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	B:C1827061
Surveillance	I:C1827061
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	B:C1518681
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	B:C0683956
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	B:C0376358
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	B:C0376358
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	B:C0008902
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	B:C0008902
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	B:C0194804
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	B:C0599755
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	B:C0194810
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	O
prostatectomy	I:C0194810
)	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	I:C0683956
for	O
underestimating	O
the	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
grade	O
group	I:C0008902
(	O
grade	O
group	I:C0008902
)	O
from	O
prostate	O
biopsies	I:C0194804
in	O
a	O
large	O
monocentric	O
cohort	I:C0599755
of	O
patients	O
treated	O
by	O
minimally	O
invasive	I:C0194810
radical	I:C0194810
prostatectomy	I:C0194810
(	O
radical	B:C0194810
prostatectomy	I:C0194810
)	O
.	O

Using	O
a	O
monocentric	B:C0242356
prospectively	I:C0242356
maintained	I:C0242356
database	I:C0242356
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	O
invasive	I:C0194810
RP	I:C0194810
between	O
2006	O
and	O
2013	O
.	O

Using	O
a	O
monocentric	O
prospectively	I:C0242356
maintained	I:C0242356
database	I:C0242356
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	B:C0194810
invasive	I:C0194810
RP	I:C0194810
between	O
2006	O
and	O
2013	O
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B:C1518681
associated	O
with	O
a	O
grade	O
group	I:C0008902
upgrade	O
from	O
biopsy	O
to	O
radical	O
prostatectomy	I:C0194810
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	O
associated	O
with	O
a	O
grade	B:C0008902
group	I:C0008902
upgrade	O
from	O
biopsy	O
to	O
radical	O
prostatectomy	I:C0194810
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	O
associated	O
with	O
a	O
grade	O
group	I:C0008902
upgrade	O
from	O
biopsy	B:C0005558
to	O
radical	O
prostatectomy	I:C0194810
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	O
associated	O
with	O
a	O
grade	O
group	I:C0008902
upgrade	O
from	O
biopsy	O
to	O
radical	B:C0194810
prostatectomy	I:C0194810
.	O

Multivariate	B:C0206031
logistic	I:C0206031
regression	I:C0206031
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	O
to	O
predict	O
upgrading	O
for	O
GG1	O
.	O

Multivariate	O
logistic	I:C0206031
regression	I:C0206031
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B:C1450294
to	O
predict	O
upgrading	O
for	O
GG1	O
.	O

Multivariate	O
logistic	I:C0206031
regression	I:C0206031
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	O
to	O
predict	O
upgrading	O
for	O
GG1	B:C0008902
.	O

Biopsy	B:C0005558
grade	O
group	I:C0008902
was	O
upgraded	O
after	O
radical	O
prostatectomy	I:C0194810
in	O
51.5	O
%	O
of	O
cases	O
.	O

Biopsy	O
grade	B:C0008902
group	I:C0008902
was	O
upgraded	O
after	O
radical	O
prostatectomy	I:C0194810
in	O
51.5	O
%	O
of	O
cases	O
.	O

Biopsy	O
grade	O
group	I:C0008902
was	O
upgraded	O
after	O
radical	B:C0194810
prostatectomy	I:C0194810
in	O
51.5	O
%	O
of	O
cases	O
.	O

Patients	O
upgraded	O
from	O
GG1	B:C0008902
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	B:C0008902
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	B:C0008902
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	B:C0194810
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	B:C2985506
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	B:C0008902
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	B:C0008902
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	B:C0005558
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	B:C0194810
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	B:C2985506
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
radical	O
prostatectomy	I:C0194810
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	O
and	O
radical	O
prostatectomy	I:C0194810
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	I:C2985506
than	O
those	O
who	O
remained	O
GG1	B:C0008902
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	B:C0008902
prostate	O
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	O
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
prostate	B:C0376358
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	O
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
prostate	O
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	B:C1384593
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
prostate	O
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	O
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	B:C0243095
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
prostate	O
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	O
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	B:C0243095
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
prostate	O
cancer	I:C0376358
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	O
digital	I:C1384593
rectal	I:C1384593
examination	I:C1384593
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-	I:C0243095
specific	I:C0243095
antigen	I:C0243095
density	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	I:C0243095
positive	I:C0243095
cores	I:C0243095
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	B:C4055400
mass	I:C4055400
index	I:C4055400
(	O
P	O
=	O
.037	O
)	O
.	O

A	O
nomogram	B:C1450294
was	O
generated	O
and	O
validated	O
internally	O
.	O

Biopsy	B:C0005558
grading	O
system	I:C1273712
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O

Biopsy	O
grading	B:C1273712
system	I:C1273712
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O

Upgrading	O
grade	B:C0008902
group	I:C0008902
from	O
biopsy	O
to	O
radical	O
prostatectomy	I:C0194810
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	I:C1518681
.	O

Upgrading	O
grade	O
group	I:C0008902
from	O
biopsy	B:C0005558
to	O
radical	O
prostatectomy	I:C0194810
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	I:C1518681
.	O

Upgrading	O
grade	O
group	I:C0008902
from	O
biopsy	O
to	O
radical	B:C0194810
prostatectomy	I:C0194810
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	I:C1518681
.	O

Upgrading	O
grade	O
group	I:C0008902
from	O
biopsy	O
to	O
radical	O
prostatectomy	I:C0194810
may	O
have	O
consequences	O
on	O
clinical	B:C1518681
outcomes	I:C1518681
.	O

A	O
nomogram	B:C1450294
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	O
patients	O
at	O
their	O
initial	O
evaluation	O
.	O

A	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	B:C0008902
patients	O
at	O
their	O
initial	O
evaluation	O
.	O

A	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	O
patients	O
at	O
their	O
initial	O
evaluation	B:C0220825
.	O

